Cargando…

Sorafenib as second‐line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma

BACKGROUND AND AIM: Currently, there is no molecular‐targeted agent that has demonstrated evidence of efficacy in patients with unresectable hepatocellular carcinoma (u‐HCC) who have developed resistance to treatment with lenvatinib (LEN). In this real‐world study, we aimed to investigate the therap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tomonari, Tetsu, Sato, Yasushi, Tanaka, Hironori, Tanaka, Takahiro, Taniguchi, Tatsuya, Sogabe, Msasahiro, Okamoto, Koichi, Miyamoto, Hiroshi, Muguruma, Naoki, Takayama, Tetsuji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Publishing Asia Pty Ltd 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7731817/ https://www.ncbi.nlm.nih.gov/pubmed/33319048 http://dx.doi.org/10.1002/jgh3.12408

Ejemplares similares

Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
por: Tomonari, Tetsu, et al.
Publicado: (2021)

Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: Three case reports
por: Tomonari, Tetsu, et al.
Publicado: (2020)

Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma including after treatment with sorafenib: Real-world evidence and in vitro assessment via protein phosphorylation array
por: Tomonari, Tetsu, et al.
Publicado: (2020)

Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve
por: Tomonari, Tetsu, et al.
Publicado: (2022)

MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma
por: Tomonari, Tetsu, et al.
Publicado: (2016)

Clinical Features and Outcomes of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma
por: Tomonari, Tetsu, et al.
Publicado: (2023)

An Adult Case of Congenital Extrahepatic Portosystemic Shunt Successfully Treated with Balloon-occluded Retrograde Transvenous Obliteration
por: Tanaka, Hironori, et al.
Publicado: (2021)

MiR-125b-5p Is Involved in Sorafenib Resistance through Ataxin-1-Mediated Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma
por: Hirao, Akihiro, et al.
Publicado: (2021)

Influence of light alcohol consumption on lifestyle-related diseases: a predictor of fatty liver with liver enzyme elevation in Japanese females with metabolic syndrome
por: Sogabe, Masahiro, et al.
Publicado: (2016)

Long-Term Survival due to Chemotherapy including Paclitaxel in a Patient with Metastatic Primary Splenic Angiosarcoma
por: Takehara, Masanori, et al.
Publicado: (2021)

APOB codon 4311 polymorphism is associated with hepatitis C virus infection through altered lipid metabolism
por: Harada, Rie, et al.
Publicado: (2018)

Influence of Alcohol Consumption on the Development of Erosive Esophagitis in Both Sexes: A Longitudinal Study
por: Sogabe, Masahiro, et al.
Publicado: (2022)

The differing influence of several factors on the development of fatty liver with elevation of liver enzymes between genders with metabolic syndrome: A cross-sectional study
por: Sogabe, Masahiro, et al.
Publicado: (2017)

Comparison of the role of alcohol consumption and qualitative abdominal fat on NAFLD and MAFLD in males and females
por: Sogabe, Masahiro, et al.
Publicado: (2022)

Differences in Several Factors in the Development of Erosive Esophagitis Among Patients at Various Stages of Metabolic Syndrome: A Cross-Sectional Study
por: Sogabe, Masahiro, et al.
Publicado: (2021)

Differences among patients with and without nonalcoholic fatty liver disease having elevated alanine aminotransferase levels at various stages of metabolic syndrome
por: Sogabe, Masahiro, et al.
Publicado: (2020)

Detection of aberrant crypt foci with image-enhanced endoscopy
por: Kagemoto, Kaizo, et al.
Publicado: (2018)

Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma
por: Sasaki, Ryu, et al.
Publicado: (2022)

Effects of audio and visual distraction on patients’ vital signs and tolerance during esophagogastroduodenoscopy: a randomized controlled trial
por: Sogabe, Masahiro, et al.
Publicado: (2020)

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
por: Chen, Yen-Yang, et al.
Publicado: (2020)

A Novel Theranostic Combination of Near-infrared Fluorescence Imaging and Laser Irradiation Targeting c-KIT for Gastrointestinal Stromal Tumors
por: Fujimoto, Shota, et al.
Publicado: (2018)

Lenvatinib as a Therapeutic Option in Unresectable Metastatic Pheochromocytoma and Paragangliomas
por: Hassan Nelson, Lauren, et al.
Publicado: (2022)

Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis
por: Zhao, Shu, et al.
Publicado: (2022)

Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy
por: Burgio, Valentina, et al.
Publicado: (2021)

Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy
por: Sekiguchi, Shuhei, et al.
Publicado: (2022)

Epidermal growth factor receptor‐targeted molecular imaging of colorectal tumors: Detection and treatment evaluation of tumors in animal models
por: Miyamoto, Yoshihiko, et al.
Publicado: (2019)

Lenvatinib-induced Interstitial Pneumonia in a Patient with Hepatocellular Carcinoma
por: Imakura, Takeshi, et al.
Publicado: (2021)

Resveratrol inhibits development of colorectal adenoma via suppression of LEF1; comprehensive analysis with connectivity map
por: Wada, Hironori, et al.
Publicado: (2022)

Real-World Effectiveness of Sorafenib versus Lenvatinib Combined with PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma
por: Chiang, Hsueh-Chien, et al.
Publicado: (2023)

Investigation of Gastroduodenal Mucosal Injury in Japanese Asymptomatic Antiplatelet Drug Users
por: Sogabe, Masahiro, et al.
Publicado: (2015)

Comparative study between sorafenib and lenvatinib as the first‐line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real‐world setting
por: Fukushima, Taito, et al.
Publicado: (2021)

Overview of Chemotherapy for Gastric Cancer
por: Sato, Yasushi, et al.
Publicado: (2023)

A Case of Unresectable Combined Hepatocellular-Cholangiocarcinoma Successfully Treated with Lenvatinib
por: Osuga, Takahiro, et al.
Publicado: (2022)

Twin Rectal Tonsils Mimicking Carcinoid or Mucosa-Associated Lymphoid Tissue Lymphoma
por: Takehara, Masanori, et al.
Publicado: (2017)

Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan
por: Kobayashi, Masahiro, et al.
Publicado: (2019)

Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma
por: Briggs, Andrew, et al.
Publicado: (2020)

A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC
por: Lee, Jaejun, et al.
Publicado: (2020)

Endoscopic Molecular Imaging: Status and Future Perspective
por: Muguruma, Naoki, et al.
Publicado: (2013)

Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma
por: Amioka, Kei, et al.
Publicado: (2022)

Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis
por: Rimini, M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9gca8q3ahefm969i9a2vhnq8mk